New Schizophrenia Drug Cobenfy (Xanomeline and Trospium Chloride) Gets FDA Approval

2024-09-28 – Health – www.everydayhealth.com


The U.S. Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) to treat schizophrenia in adults, offering the first new treatment in decades for the psychiatric disorder.e60dc2a1-f33c-4a05-9b50-8e3e8e59762958f19463-a3e1-4a5e-992e-622af04e95d3 “This approval offers a new alternative to the antipsychotic medications people with schizophrenia have previously been prescribed,” Tiffany Farchione, MD, director of the division of psychiatry in the Office of Neuroscience in the FDA’s Center for Drug Evaluation and Research, said in the FDA statement. Cobenfy, previously called KarXT, is the first drug in a new family of medicines known as muscarinic agonists that work by activating two receptors in the brain. Unlike previous antipsychotics, which target dopamine receptors in the brain, Cobenfy homes in on cholinergic receptors, the FDA said in its statement. “Importantly, because KarXT acts by a fundamentally different mechanism, it does not…
Read the full article here.